膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Annexin A2 (ANXA2) ,etc. by FLIA (Flow Luminescence Immunoassay)
ANX-A2; ANX2L4; CAL1H; LIP2; LPC2; LPC2D; P36; PAP-IV; Protein I; Chromobindin-8; Calpactin-1 heavy chain; Lipocortin II; Placental anticoagulant protein IV
(注:單次混測多因子不超過8個指標(biāo) )
- 編號LMB944Mu
- 物種Mus musculus (Mouse,小鼠)相同的名稱,不同的物種。
- 實驗方法雙抗夾心
- 反應(yīng)時長3.5h
- 檢測范圍0.01-10ng/mL
- 靈敏度最小可檢測劑量小于等于0.003 ng/mL.
- 樣本類型Serum, plasma, tissue homogenates and other biological fluids
- 下載英文說明書 中文說明書
- 規(guī)格8指標(biāo)數(shù)7指標(biāo)數(shù)6指標(biāo)數(shù)5指標(biāo)數(shù)4指標(biāo)數(shù)3指標(biāo)數(shù)2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價格¥ 2562¥ 2660¥ 2808¥ 3005¥ 3202¥ 3497¥ 3941計算器 ¥ 4926 添加到價格計算器
- 欲了解實際交易價格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
本試劑盒用于檢測膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光發(fā)光法),經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制,不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測,因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光發(fā)光法)(加標(biāo)樣品),重復(fù)測定并計算其均值,回收率為測定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 90-102 | 97 |
EDTA plasma(n=5) | 90-97 | 94 |
heparin plasma(n=5) | 86-96 | 92 |
sodium citrate plasma(n=5) | 79-104 | 87 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次,分別計算不同濃度樣本的平均值及SD值。
批間差:選取3個不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定,每個樣本使用同一試劑盒重復(fù)測定8次,分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光發(fā)光法),并倍比稀釋成1:2,1:4,1:8,1:16的待測樣本,線性范圍即為稀釋后樣本中膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光發(fā)光法)含量的測定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 90-103% | 80-90% | 97-104% | 80-105% |
EDTA plasma(n=5) | 82-102% | 81-104% | 84-96% | 93-101% |
heparin plasma(n=5) | 85-99% | 90-97% | 93-101% | 85-101% |
sodium citrate plasma(n=5) | 94-102% | 81-97% | 90-98% | 86-104% |
穩(wěn)定性
經(jīng)測定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響,實驗室的環(huán)境條件需盡量保持一致,尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進(jìn)行操作可減少人為誤差。
實驗流程
1. 實驗前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品、樣本、磁珠)標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL,
37°C酶標(biāo)板振蕩器孵育90分鐘;
3. 磁吸甩干,加檢測溶液A100μL,37°C酶標(biāo)板振蕩器孵育60分鐘;
4. 磁吸洗板3次;
5. 加檢測溶液B100μL,37°C振動孵育30分鐘;
6. 磁吸洗板3次;
7. 加鞘液100μL,旋渦震蕩2分鐘后讀數(shù)。
實驗原理
將膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體包被于磁珠,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠,其中的膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體,將未結(jié)合的生物素化抗體洗凈后,加入PE標(biāo)記的親和素,再次徹底洗滌后即可上機讀數(shù)。MFI值和樣品中的膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
編號 | 適用物種:Mus musculus (Mouse,小鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPB944Mu02 | 膜聯(lián)蛋白A2(ANXA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPB944Mu01 | 膜聯(lián)蛋白A2(ANXA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APB944Mu01 | 膜聯(lián)蛋白A2(ANXA2)活性蛋白 | Cell?culture;?Activity?Assays. |
PAB944Mu01 | 膜聯(lián)蛋白A2(ANXA2)多克隆抗體 | WB; IHC |
PAB944Mu02 | 膜聯(lián)蛋白A2(ANXA2)多克隆抗體 | WB; IHC; ICC; IP. |
SEB944Mu | 膜聯(lián)蛋白A2(ANXA2)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMB944Mu | 膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Journal of Cellular Biochemistry | Subcellular proteome analysis unraveled annexin A2 related to immune liver fibrosis[PubMed: 20225235] |
World Journal of Gastroenterology | Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma[PubMed: PMC3491596] |
Oncology Letters | Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis[PubMed: PMC3742823] |
Ibrahim | Annexin A2 Versus Afp as An Efficient Diagnostic Serum Marker for Hepatocellular Carcinoma[Ghrnet: Source] |
European Journal of Clinical Microbiology & Infectious Diseases | Serum annexin A2 levels in acute brucellosis and brucellar spondylodiscitis[Pubmed:24853056] |
Biomedicine & Pharmacotherapy | Circulating annexin A2 as a biomarker in gastric cancer patients: Correlation with clinical variables[Pubmed:25661364] |
Hepat Mon | Serum Levels of Annexin A2 as a Candidate Biomarker for Hepatic Fibrosis in Patients With Chronic Hepatitis B[PubMed: 26587036] |
Tumour Biol | Up-regulation of annexin A2 expression predicates advanced clinicopathological features and poor prognosis in hepatocellular carcinoma[PubMed: 26109000] |
Biomed Pharmacother | Circulating[PubMed: 25661364] |
Tumour Biol | Evaluation of annexin A2 and as potential biomarkers for hepatocellular carcinoma[PubMed: 26189841] |
Eur J Clin Invest | Stairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population[PubMed: 26081791] |
Journal of Oral and Maxillofacial Surgery | Serum?Annexin?A2?Level?Is?Associated?With?Diagnosis?and?Prognosis?in?Patients?With?OralSquamous?Cell?Carcinoma.[pubmed:27889534] |
Pregnancy Hypertens | Assessment of annexin A5 and annexin A2 levels as biomarkers for pre-eclampsia: A pilot study.[pubmed:28501283] |
Mol Nutr Food Res. | Epigallocatechin gallate induces an up-regulation of LDL receptor accompanied by a reduction of PCSK9 via the annexin A2-independent pathway in HepG2 cells.[pubmed:28181408] |
Archives of Gynecology and Obstetrics | Expression of annexin A2 in adenomyosis and dysmenorrhea[Pubmed: 31183557] |
Cancers | Extracellular Vesicles-Based Biomarkers Represent a Promising Liquid Biopsy in Endometrial Cancer[Pubmed: 31842290] |
PLASMA BIOMARKER FOR OVARIAN CANCER[] | |
Diagnostics | Diagnostic Value of Plasma Annexin A2 in Early-Stage High-Grade Serous Ovarian Cancer. Diagnostics 2021, 11, 69[33406648] |
ADVANCED RESEARCHES | Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C[] |
Cancer Cell International | Bufalin Induced Mitochondrial Dysfunction Promotes Apoptosis of Glioma Cells by Regulating Annexin A2 and DRP1 Proteins[] |
Cancer Cell Int | Bufalin induces mitochondrial dysfunction and promotes apoptosis of glioma cells by regulating Annexin A2 and DRP1 protein expression[34376212] |